+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations
E

Actively Recruiting

Healthy Volunteer

Post Operative Atrial Fibrillation POAF is a frequent complication after cardiac surgery, affecting over half of patients depending on their health and the type of surgery. This trial studies whether adding preventive ablation and exclusion of the Left Atrial Appendage during routine cardiac surgery can lower the chances of developing POAF and ongoing atrial fibrillation in patients at risk who have not yet experienced these heart rhythm problems. Participants are randomly assigned to one of two groups one group will have the standard cardiac surgery plus the use of the Isolator Synergy EnCompass Ablation System and the AtriClip Left Atrial Appendage Exclusion System, while the other group will have the standard cardiac surgery alone without these additional procedures. The preventive devices are applied during the planned surgery requiring cardiac bypass and opening of the heart lining. During the study, participants will be monitored closely up to 30 days post-surgery to assess safety and effectiveness, with further follow-up extending to three years to evaluate longer-term outcomes. The main focus is on measuring the occurrence of atrial fibrillation after surgery and any complications related to the procedures. The trial is sponsored by AtriCure, Inc. and aims to improve prevention strategies for atrial fibrillation after heart surgery.

Age: 65Years +All GendersPhase Not Applicable
37 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Pulse Biosciences CellFX nsPFA Cardiac Surgery System to treat atrial fibrillation AF during heart surgery. This prospective, multicenter, non-randomized single-arm study involves adults with paroxysmal or persistent AF undergoing cardiac surgical procedures. The study aims to assess freedom from AF and related arrhythmias after 3 to 6 months following the procedure, as well as monitor acute major adverse events within 30 days post-surgery. Participants will undergo cardiac ablation using the CellFX nsPFA Cardiac Clamp during concomitant cardiac surgery, which includes isolation of the left and right pulmonary veins and the left atrial posterior wall. The left atrial appendage will also be excluded or removed. The posterior wall isolation can be performed via epicardial lesions alone or combined epicardial and endocardial approaches when the left atrium is open. During the study, participants will be evaluated for heart rhythm outcomes and safety events. Assessments include electrical isolation immediately post-ablation, monitoring freedom from atrial arrhythmias up to 12 months, and patient-reported quality of life measures at 6 and 12 months. The study also tracks serious adverse events such as death, stroke, or bleeding within 30 days after surgery. The total participation spans at least 12 months, including follow-up visits to monitor health and heart function.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
3 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
N

Actively Recruiting

Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.

All AgesAll Genders
630 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
R

Actively Recruiting

This research aims to collect real-world information about the treatment of lesions in the peripheral vasculature, focusing on patients who may not have been included in previous Peripheral Vascular Disease PVD studies. It evaluates the use of commercially available drug-eluting devices made by Boston Scientific Corporation to better understand their application and health economic impact globally. Participants in this registry receive treatment with Boston Scientific drug-eluting devices such as the Ranger14 Paclitaxel-Coated PTA Balloon Catheter and the ELUVIA14 Drug-Eluting Vascular Stent System. The study is observational and includes patients from multiple countries, with follow-up lasting up to 2 years in most countries and up to 5 years in China. Some participants at select sites will also complete additional assessments like quality of life questionnaires, six-minute walk tests, and healthcare utilization data collection. Throughout the study, participants undergo assessments based on standard care procedures. Researchers will monitor major adverse events and lesion patency at 12 months. Data collected includes health economics and patient outcomes to support the safe use of these devices. The total study duration extends up to 5 years depending on location, with scheduled follow-ups to gather ongoing information about treatment effects and patient health.

Age: 18Years +All Genders
86 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating two ways to improve genetic testing communication for first-degree relatives of patients newly diagnosed with colorectal cancer. About 30% of colorectal cancer cases may have a genetic cause, and identifying inherited variants can help at-risk relatives understand their cancer risk. This study compares patient-led communication versus provider-led communication to see which better encourages relatives to undergo genetic testing. Participants first provide blood samples for genetic testing. Those with pathogenic germline variants and their first-degree relatives are assigned to one of two groups one where relatives get information from the patient proband-mediated and another where relatives get information directly from healthcare providers provider-mediated. Patients are followed for up to three years, while relatives are followed for one year. During the trial, participants complete questionnaires and genetic education. Researchers measure how many relatives complete genetic testing within six months and how many with genetic variants undertake prevention efforts within twelve months. The study also explores subgroup differences and overall disease-free survival of patients at three years. Genetic testing and communication outcomes are closely monitored to assess impact.

Age: 18Years +All GendersPhase Not Applicable
365 locations
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for treating non-paroxysmal atrial fibrillation, including persistent and longstanding persistent forms. This multi-center, single-arm, prospective study involves up to 160 participants undergoing concomitant cardiac surgery. The goal is to support an expansion of product labeling for these devices to include treatment of persistent atrial fibrillation. Participants will receive surgical ablation during their planned open-heart surgery. This includes the use of the Cardioblate iRF and CryoFlex hand held devices, with required procedures such as the Cox Maze IV lesion set and closure or amputation of the left atrial appendage. The study does not include a control group and follows patients for 12 months after the procedure. During the study, participants will be monitored for major adverse events up to 30 days post-procedure or hospital discharge and assessed for freedom from atrial fibrillation, atrial flutter, or atrial tachycardia from 6 to 12 months post-procedure. Additional safety and efficacy measures will be collected, including pacemaker implantation rates, quality of life surveys, and procedural success. Follow-up visits and evaluations will continue for 12 months to monitor outcomes and safety.

Age: 18Years +All GendersPhase Not Applicable
15 locations

1-10 of 16

1